aTYR PHARMA (ATYR) Enterprise Value (2015 - 2026)

aTYR PHARMA (ATYR) has reported Enterprise Value for 12 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 99.68% year-over-year to $1.2 million; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (down 99.68% YoY), and the FY2025 full-year result was -$2.1 million, down 100.91% from the prior year.
• Enterprise Value fell to $1.2 million in Q2 2026 per ATYR's latest filing, from $9.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at $390.3 million in Q2 2025 and bottomed at -$26.6 million in Q1 2023.
• Historically, Enterprise Value has averaged $54.3 million across 5 years, with a median of $9.6 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value tumbled 428.92% in 2023, then surged 2642.81% in 2024.
• Over 5 years, Enterprise Value stood at -$1.7 million in 2022, then sank by 428.92% to -$9.1 million in 2023, then soared by 2642.81% to $231.9 million in 2024, then plunged by 100.91% to -$2.1 million in 2025, then jumped by 158.77% to $1.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $1.2 million, $9.8 million, and -$2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.